ACIT Vs Lyka Labs Ltd. (ITAT Mumbai)
In the case of ACIT vs. Lyka Labs Ltd., the primary issue revolved around the tax treatment of a non-compete fee received by Lyka Labs Ltd. from its joint venture, Lyka Hetro Health Care Limited (LHHCL). The dispute spanned the Assessment Year (A.Y.) 2002-03 and involved differing interpretations between the Revenue and the assessee regarding whether the receipt should be treated as a revenue or capital receipt.
Background and Facts
Lyka Labs Ltd., engaged in pharmaceutical manufacturing, received a total sum of Rs. 49.8 crores from LHHCL under various heads:
- Non-compete fees: Rs. 10 crores
- Assignment of registered trade mark: Rs. 15 crores
- Assignment of unregistered trade mark: Rs. 10 crores
- Marketing information and consultancy: Rs. 7.4 crores
- Scientific know-how and technical information: Rs. 7.4 crores
The dispute specifically focused on the non-compete fee of Rs. 10 crores. The Assessing Officer (AO) treated this amount as a revenue receipt, subjecting it to tax for the A.Y. 2002-03. On appeal, the Commissioner of Income Tax (Appeals) (CIT(A)) overturned this decision, categorizing the non-compete fee as a capital receipt, not taxable for that assessment year.
Legal Arguments
The Revenue’s primary contention was that the non-compete fee should be considered a revenue receipt because Lyka Labs Ltd. had not relinquished its entire business source. They argued that the restrictive covenant was not absolute since Lyka Labs Ltd. retained the option to reduce its shareholding in LHHCL below 26% and continue competing in the market. The Revenue relied on the decision in Rai Bahadur Jairam Valji’s case to support their stance that such receipts are revenue in nature.
